The 2021 WHO classification of tumors of the central nervous system (CNS) lists MYCN among the genes characteristically altered in diffuse pediatric-type glioma, spinal ependymoma, as well as SHH-activated and non-WNT/non-SHH medulloblastoma [17]. Here, MYCN is linked to medulloblastoma.